Oral fluoropyrimidines: A closer look at their toxicities

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 5, 1999, Pages 475-480

  Macdonald, John S ^a  

^a Saint Vincents Comprehensive Cancer Center   (United States)

Author keywords

Adverse reactions; Capecitabine Eniluracil; Emitefur (BOF A2); Oral fluorinated pyrimidines; S 1; Tegafur; UFT

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5 ETHYNYLURACIL; CAPECITABINE; EMITEFUR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; PACLITAXEL; PROCHLORPERAZINE; UFT;

ABDOMINAL CRAMP; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSESTHESIA; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; SKIN ALLERGY; SKIN DISEASE; SKIN TOXICITY; THROMBOCYTOPENIA; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; TEGAFUR; URACIL;

EID: 0033508649     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199910000-00011     Document Type: Article

References (49)

1. Macdonald J. Adjuvant therapy for colon cancer. CA Cancer J Clin 1997;47:243-56.
2. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5:1559-65.
3. Blanke C, Kasimis B, Schein P, et al. Phase II study of trimetrexate fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol 1997;15:915-20.
4. Wadler S, Schwanz E, Goldman M, et al. Fluorouracil and recombinant alpha-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;7:1769-75.
5. Poon M, O'Connell M, Wieand H, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;9:1967-72.
6. O'Dwyer P, Paul A, Walczak J, et al. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 1990;8:1497-1503.
7. Lokich J, Ahlgren J, Gullo J, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989;7:425-32.
8. Leichman C, Fleming T, Muggia F, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995;13:1303-11.
9. Hansen R, Ryan L, Anderson T, et al. Phase ID study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 1996;88:668-74.
10. Diasio R. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-37.
11. Etienne M, Lagrange J, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994;12:2248-53.
12. Milano G, Etienne M. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review). Anticancer Res 1994;14:2295-7.
13. Friedman M, Ignoffo R. A review of the United States clinical experience of the fluoropyrimidine, Ftorafur (NSC-148958). Cancer Treat Rev 1980;7:205-13.
14. Valdivieso T, Bodey G, Gottlieb J, Freireich E. Clinical evaluation of ftorafur (pyrimidine-deosyribox N1,-2′furanddyl-5-fluorouracil). Cancer Res 1976;36:1821-4.
15. Muggia F, Xiaoyang W, Spicer D, et al. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. Clin Cancer Res 1996;2:1461-7.
16. Meropol N, Rustum Y, Petrelli N, et al. A phase 1 and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol 1996;37:581-6.
17. Pazdur R, Lassere Y, Diaz-Canton E, et al. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14 day schedule. Invest New Drugs 1997;15:123-8.
18. Pazdur R, Lassere Y, Diaz-Canton E, et al. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28 day schedule. Cancer Invest 1998;16:145-51.
19. Priest D, Schmitz J, Bunni M, Stuart R. Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst 1991; 83:1806-12.
20. Malik S, Talbot D, Clarke P, et al. Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 1990;62: 1023-5.
21. Pazdur R, Lassere Y, Rhodes V, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994; 12:2296-300.
22. Saltz L, Leichman C, Young C, et al. A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. Cancer 1995; 75:782-5.
23. González-Barón M, Feliu J, de la Gandara I, et al. Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 1995;31A:2215-9.
24. Feliu J, González-Barón M, Espinosa E, et al. Uracil and tegafur modulated with leucovorin. Cancer 1997;79:1884-9.
25. Ichikura T, Tomimatsu S, Okusa Y, et al. Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low dose leucovorin for patients with gastric cancer. Cancer Chemother Pharmacol 1996;38:401-5.
26. Budman D, Meropol N, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998;16:1795-1802.
27. Hughes M, Planting A, Twelves C, et al. A phase I study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic solid cancer [Abstract]. Ann Oncol 1996;7(suppl 1):87.
28. Taguchi T, Ishitani F, Saitoh K, et al. A Japanese phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors [Abstract]. Ann Oncol 1996;7(suppl 1):87.
29. Findlay M, Van Cutsem E, Kocha W, et al. A randomized phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer [Abstract]. Proc Am Soc Clin Oncol 1997;16:227a.
30. O'Shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase II study of Xeloda (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged ≥55 years [Abstract], Proc Am Soc Clin Oncol 1998;17:103a.
31. Blum J, Buzdar A, LaRusso P, et al. A multicenter phase II trial of Xeloda (capecitabine) in paclitaxel-refractory metastatic breast cancer [Abstract]. Proc Am Soc Clin Oncol 1998;17:125a.
32. O'Reilly S, Moiseyenko V, Talbot D, et al. A randomized phase II study of Xeloda (capecitabine) vs paclitaxel in breast cancer patients failing previous anthrocycline therapy [Abstract]. Proc Am Soc Clin Oncol 1998;17:163a.
33. Koury P, Villalona-Clero M, Blum J, et al. Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer [Abstract]. Proc Am Soc Clin Oncol 1998;17:206a.
34. Baker S, Khor S, Adjei A, et al. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1996;14:3085-96.
35. Peters G, Van Groenningen C, Schmoage J, et al. Phase I clinical and pharmacokinetic study of S-1, an oral 5-fluorouracil (5-FU)-based antineoplastic agent [Abstract]. Proc Am Soc Clin Oncol 1997;16:227a.
36. Fuji M, Kansaki J, Satake B, et al. Early phase II study of S-1 in patients with advanced head and neck cancer [Abstract]. Proc Am Soc Clin Oncol 1996;15:316.
37. Taguchi T, Horikoshi N, Kinoshita H, et al. Early phase II study of S-1 in patients with advanced breast cancer [Abstract]. Proc Am Soc Clin Oncol 1996;15:121.
38. Horikoshi N, Mitachi Y, Sakata Y, et al. S-1, new oral fluoropyrimidine, is very active in patients with advanced gastric cancer (early phase II study) [Abstract]. Proc Am Soc Clin Oncol 1996; 15:206.
39. Nakai Y, Furuse K, Ohta M, et al. Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study. Acta Oncol 1994;33:523-6.
40. Sugimachu K, Maehara Y. Clinical effect of a new 5-FU derivative BOF-A2 for patients with advanced gastric cancer: a multicenter late phase II study [Meeting abstract]. Can J Infect Dis 1995; 6(suppl C):209C.
41. Kobayashi S, Maekawa T, Sakakibara N. Multicenter late phase II study of BOF-A2 in colorectal cancer [Meeting abstract]. Can J Infect Dis 1995;6(suppl C):289C.
42. Fraile R, Baker L, Buroker T, Horwitz J, Vaitkevicius V. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous infusion, and by slow infusion. Cancer Res 1980;40:2223-8.
43. Milano G. 5-Fluorouracil infusional schedules. J Infus Chemother 1992;3:160-3.
44. Van Groenningen C, Pinedo H, Heddes J, et al. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass-spectrophotometric method in patients on a dose escalation schedule. Cancer Res 1988;48:6956-61.
45. Trump D, Egorin M, Forrest A, et al. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72 h continuous infusion with and without dipyridimole. J Clin Oncol 1991;9: 2027-35.
46. Petrelli N, Douglass H, Herrera L. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase II trial. J Clin Oncol 1989;7:1419-26.
47. The Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8.
48. Buroker T, O'Connell M, Wieand S, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14-20.
49. Hoff P, Pazdur R, Benner S, Canetta R. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 1998;9:479-90.